122 related articles for article (PubMed ID: 11981003)
1. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Van Poznak C; Tan L; Panageas KS; Arroyo CD; Hudis C; Norton L; Seidman AD
J Clin Oncol; 2002 May; 20(9):2319-26. PubMed ID: 11981003
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.
Modi S; DiGiovanna MP; Lu Z; Moskowitz C; Panageas KS; Van Poznak C; Hudis CA; Norton L; Tan L; Stern DF; Carter D; Seidman AD
Cancer Invest; 2005; 23(6):483-7. PubMed ID: 16203655
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H; Yu D; Wang J; Qiu T; Yang J; Wang L
Anticancer Drugs; 2008 Mar; 19(3):317-23. PubMed ID: 18510179
[TBL] [Abstract][Full Text] [Related]
5. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
6. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
[TBL] [Abstract][Full Text] [Related]
7. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
8. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer.
Sezgin C; Karabulut B; Uslu R; Sanli UA; Goksel G; Zekioglu O; Ozdemir N; Goker E
J Chemother; 2005 Feb; 17(1):96-103. PubMed ID: 15828451
[TBL] [Abstract][Full Text] [Related]
9. Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer.
Cirak Y; Furuncuoglu Y; Yapicier O; Alici S; Argon A
Int J Clin Exp Pathol; 2015; 8(5):5345-53. PubMed ID: 26191236
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
12. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.
Schmidt M; Bachhuber A; Victor A; Steiner E; Mahlke M; Lehr HA; Pilch H; Weikel W; Knapstein PG
J Cancer Res Clin Oncol; 2003 May; 129(5):295-302. PubMed ID: 12715164
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
15. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Hamilton A; Larsimont D; Paridaens R; Drijkoningen M; van de Vijver M; Bruning P; Hanby A; Houston S; Treilleux I; Guastalla JP; Van Vreckem A; Sylvester R; Piccart M
Clin Breast Cancer; 2000 Oct; 1(3):233-40; discussion 241-2. PubMed ID: 11899648
[TBL] [Abstract][Full Text] [Related]
16. [HER-2 and ER expression in prediction of chemo-sensitivity of taxane for advanced breast cancer].
Liu F; Jiang ZF; Song ST; Sun JZ; Zhang SH; Feng SQ
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):449-51. PubMed ID: 17152493
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
Harris LN; Broadwater G; Lin NU; Miron A; Schnitt SJ; Cowan D; Lara J; Bleiweiss I; Berry D; Ellis M; Hayes DF; Winer EP; Dressler L
Breast Cancer Res; 2006; 8(6):R66. PubMed ID: 17129383
[TBL] [Abstract][Full Text] [Related]
19. Association between immunohistochemical expression of topoisomerase IIalpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer.
Manna Edel F; Teixeira LC; Alvarenga M
Tumori; 2006; 92(3):222-9. PubMed ID: 16869240
[TBL] [Abstract][Full Text] [Related]
20. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer.
Formenti SC; Spicer D; Skinner K; Cohen D; Groshen S; Bettini A; Naritoku W; Press M; Salonga D; Tsao-Wei D; Danenberg K; Danenberg P
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):397-405. PubMed ID: 11872285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
